M. C. Dalakas and R. Hohlfeld, “Polymyositis and Dermatomyositis,” The Lancet, Vol. 362, No. 9388, 2003, pp. 971-982. doi:10.1016/S0140-6736(03)14368-1

has been cited by the following article:

• TITLE: Use of Rituximab in Refractory Dermatomyositis: A Case Report

  AUTHORS: K. Grover, R. Peshin

  KEYWORDS: Dermatomyositis; Rituximab

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.3 No.1, February 21, 2013

  ABSTRACT: We report a case of a 56-year-old female with a confirmed diagnosis of Dermatomyositis on muscle biopsy, which was refractory to 5 different disease modifying drugs as well as intravenous immunoglobulins and symptoms improved dramatically with a single course of Rituximab. We hereby wish to highlight the importance of Rituximab in this highly resistant case and that anti CD 20 biologic drugs can be considered as standard treatment protocol in refractory Dermatomyositis.